|4.||Primary Myelofibrosis (Myelosclerosis)
|5.||Myeloproliferative Disorders (Myeloproliferative Disorder)
|1.||Tefferi, Ayalew: 25 articles (12/2015 - 01/2004)|
|2.||Vannucchi, Alessandro M: 21 articles (05/2015 - 11/2007)|
|3.||Verstovsek, Srdan: 16 articles (09/2015 - 01/2003)|
|4.||Guglielmelli, Paola: 14 articles (05/2015 - 11/2007)|
|5.||Mesa, Ruben A: 13 articles (11/2015 - 04/2005)|
|6.||Tefferi, A: 13 articles (01/2015 - 09/2000)|
|7.||Barbui, Tiziano: 13 articles (10/2014 - 05/2003)|
|8.||Rambaldi, Alessandro: 13 articles (10/2014 - 08/2010)|
|9.||Gisslinger, Heinz: 11 articles (08/2014 - 09/2002)|
|10.||Hasselbalch, Hans Carl: 10 articles (08/2015 - 12/2007)|
|1.||Hydroxyurea (Hydrea)FDA LinkGeneric
12/01/2009 - "The aim of the present study was to determine the effect of ASA and hydroxyurea on platelet, leukocyte functions and on formation of platelet/leukocyte conjugates in vivo in patients with essential thrombocythemia. "
06/01/2015 - "Reactivation of hepatitis B virus during treatment with hydroxyurea in an elderly patient with essential thrombocythemia."
01/01/2013 - "Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment."
01/01/2013 - "Acquired melanonychia in chilean patients with essential thrombocythemia treated with hydroxyurea: a report of 7 clinical cases and review of the literature."
12/01/2012 - "Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea."
|2.||anagrelide (Agrylin)FDA LinkGeneric
03/01/2013 - "Although anagrelide is widely used for the treatment of essential thrombocythemia (ET) in the USA and Europe, it is not licensed in Japan. "
05/01/2008 - "We can conclude that anagrelide is an effective and safe drug for pretreated patients with essential thrombocythemia."
01/01/2000 - "We present herein studies carried out in 17 patients with essential thrombocythemia before treatment with anagrelide and on remission. "
07/01/2000 - "Essential thrombocythemia-related microvascular thrombotic and hemorrhagic symptoms disappeared with the normalization of platelet count in all cases during maintained remission of essential thrombocythemia by long term continuous anagrelide treatment with a follow-up period of between 2 and 6 years. "
07/01/2000 - "The platelet counts before anagrelide treatment and during maintained remission of essential thrombocythemia by anagrelide were 980 (range, 610-2030) and 378 (range, 212-546) x 10(9)/L, respectively. "
|3.||Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
10/01/1999 - "To determine whether 50 mg/day is as effective as 100 mg/day for the prophylaxis of microvascular circulation disturbances in essential thrombocythemia, a randomized trial comparing low-dose aspirin 50 mg versus 100 mg at platelet counts between 400 and 1,000 up to 1,500 x 10(9)/L is recommended. "
01/01/2008 - "Aspirin provides satisfactory protection against thrombotic episodes in essential thrombocythemia (ET), but at higher platelet counts has been less effective. "
01/01/1997 - "Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin."
04/01/2006 - "Future studies should assess primarily the efficacy and safety of aspirin in essential thrombocythemia, and test the possible use of more aggressive antithrombotic strategies in high-risk polycythemic patients."
11/01/2015 - "Cytoreductive therapy, with or without low-dose aspirin, is the mainstay of thrombotic risk reduction in patients with essential thrombocythemia (ET), but the optimal choice of agent remains unclear. "
|4.||Interferon-alpha (Interferon Alfa)FDA Link
12/01/1999 - "The ability of Interferon alpha (alpha-IFN) to alter the natural history of essential thrombocythemia (ET) and induce sustained hematologic remission would provide further impetus to consider this agent in younger patients with this disease and may influence the decision to commence treatment in asymptomatic patients. "
12/01/1999 - "Long-term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia."
01/01/2009 - "We report a further case of uneventful full term pregnancy with the use of interferon-alpha for maternal essential thrombocythemia which suggests that interferon-alpha could be considered as an effective and safe treatment during pregnancy for women with essential thrombocythemia. "
10/15/2007 - "Long-lasting partial remission by Interferon-alpha treatment in a child with essential thrombocythemia."
03/01/1998 - "The efficacy of alfa-interferon (alfa-IFN) in essential thrombocythemia (ET) patients has been reported by several authors. "
10/01/2005 - "In high-risk essential thrombocythemia sustained treatment with pegylated interferon is effective and safe in reducing platelet counts with a toxicity comparable to that of conventional interferon."
03/01/2013 - "Distinct efficacy of pegylated-interferon α2a and α2b during treatment of essential thrombocythemia."
10/01/2005 - "We evaluated the efficacy and toxicity of pegylated interferon in high-risk essential thrombocythemia in a phase II trial. "
10/01/2005 - "Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study."
12/10/2015 - "Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations."
|6.||Busulfan (Busulfex)FDA Link
02/01/1997 - "[Complete remission of essential thrombocythemia after recovery from severe bone marrow aplasia induced by busulfan treatment]."
03/01/1990 - "The purpose of this study was to determine which factors were associated with an increased risk of thrombo-hemorrhagic complications in a historical cohort of 100 consecutive and unselected patients with essential thrombocythemia (ET) in whom busulfan treatment was given when platelets were more than 1,000 x 10(9)/L and/or a major thrombotic or hemorrhagic event occurred. "
09/01/2007 - "Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia."
02/01/1997 - "She was diagnosed as essential thrombocythemia (ET), and treated with 2 mg of busulfan daily for 3 months until her platelet count decreased to 33.1 x 10(4)/microliter. "
04/01/1995 - "A 61-year-old man with essential thrombocythemia was treated with busulfan intermittently since April, 1991. "
05/01/1993 - "The efficacy of a single dose of MCNU 150 mg was evaluated in nine symptomatic patients with essential thrombocythemia (ET). "
06/01/1995 - "A 64-year-old female diagnosed for essential thrombocythemia was treated with MCNU 50 mg four times in the course of the disease. "
09/01/1993 - "He received ranimustine (MCNU) with a diagnosis of essential thrombocythemia. "
05/01/1993 - "MCNU in the treatment of essential thrombocythemia--a pilot study."
11/01/2002 - "We studied the therapeutic effectiveness of chemotherapy by ranimustine (MCNU) for essential thrombocythemia (ET) in 14 ET patients over 60 years of age. "
|8.||Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/01/2013 - "The present report describes two chronic myelogenous leukemia (CML) patients with the JAK2-V617F mutation who were in complete hematologic and cytogenetic remission and subsequently developed clinical features of essential thrombocythemia under treatment with tyrosine kinase inhibitors. "
03/01/2006 - "The major incentives for this review have been the recent description of an activating JAK2 tyrosine kinase mutation (JAK2 (V617F)) in essential thrombocythemia, related myeloproliferative disorders, and the impact on clinical practice from the publication of a major treatment trial. "
07/13/2010 - "The discovery of activating mutations of the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and primary myelofibrosis has lead to in vitro and animal model studies that promise to lead to therapeutic advances."
11/01/2007 - "Recent studies identified an activating mutation in the JAK2 tyrosine kinase (JAK2V617F) in most patients with polycythemia vera and in approximately half of those with essential thrombocythemia and primary myelofibrosis. "
12/01/2012 - "The prevalence of JAK2V617F tyrosine kinase mutation differs between various variants of myelofibrosis with the higher detection rate for patients with post-polycythemia vera myelofibrosis (post-PV MF; 91%) if compared to primary myelofibrosis (PMF; 45%) and post-essential thrombocythemia myelofibrosis (post-ET MF; 39%). "
|9.||Pipobroman (Vercyte)FDA Link
01/23/1988 - "[Efficacy of pipobroman in the treatment of essential thrombocythemia]."
11/01/1984 - "Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120). "
11/01/1984 - "Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients."
08/01/2004 - "Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman."
01/01/1996 - "Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman."
05/21/2015 - "JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib."
07/01/2013 - "Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF)."
03/01/2012 - "We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy. "
03/05/2012 - "With the approval of ruxolitinib by the US Federal Drug Administration in November 2011 for high-risk and intermediate-2 risk myelofibrosis, a change in paradigm has occurred in the management of a subset of myeloproliferative neoplasms (MPN): primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. "
03/01/2015 - "This case report discusses a 76-year-old man with a history of prefibrotic post-essential thrombocythemia myelofibrosis on ruxolitinib, who developed anemia, thrombocytopenia, and leukocytosis with peripheral blasts. "
01/01/1998 - "Six years after treatment he had a progressive increase in the platelet count and was diagnosed as essential thrombocythemia. "
11/01/2007 - "Essential thrombocythemia after treatment of non-Hodgkin's lymphoma."
01/01/1995 - "Multiple myeloma after treatment of essential thrombocythemia."
09/15/1998 - "This study was conducted to evaluate further the efficacy and safety of rIFN-alpha-2b in a large group of patients with polycythemia vera, essential thrombocythemia, or agnogenic myeloid metaplasia and to determine maintenance of response after treatment discontinuation. "
01/01/2000 - "[Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer]."
03/01/1975 - "[A case of essential thrombocythemia diagnosed after splenectomy (author's transl)]."
06/01/1966 - "[The treatment of hemorrhagic thrombocythemia in patients after splenectomy, by radioactive phosphorous]."
04/15/1965 - "[HEMORRHAGIC THROMBOCYTHEMIA AND ITS POSSIBLE RELATIONS TO SPLENECTOMY]."
04/01/2002 - "We report a patient with splenic vein thrombosis (SVT) in whom splenectomy resulted in the unmasking of essential thrombocythemia (ET). "
04/01/2002 - "Splenectomy in a case of splenic vein thrombosis unmasks essential thrombocythemia."
|3.||Combination Drug Therapy (Combination Chemotherapy)
01/01/1984 - "Twenty-seven patients with essential thrombocythemia were treated with combination chemotherapy consisting of weekly intravenous thiotepa (until the platelet count fell below 1,000 X 10(3)/cu mm) and daily chlorambucil (until a sustained remission, platelet count less than 400 X 10(3)/cu mm). "
11/01/2006 - "A diagnosis of essential thrombocythemia was made and the treatment was initiated with combination chemotherapy and maintained by prednisolone and busulfan. "
|5.||Drug Therapy (Chemotherapy)
07/01/2008 - "Pharmacotherapy of essential thrombocythemia."
01/01/2000 - "Blastic transformation of essential thrombocythemia (ET) preceded by chemotherapy is occasionally described in the literature. "
07/01/1992 - "A 51-year-old woman with no history of prior chemotherapy or radiation therapy was diagnosed with essential thrombocythemia (ET) according to the diagnostic criteria established by the Polycythemia Vera Study Group (PVSG). "
12/01/2003 - "We report on a case of essential thrombocythemia evolved to a myelodysplastic syndrome and finally, to an overt myeloid leukaemia, refractory to chemotherapy. "
08/01/1993 - "A 49-year-old woman with a four year history of therapy resistant essential thrombocythemia, progressed to acute leukemia that also proved refractory to chemotherapy. "